Hepatopulmonary Syndrome clinical trials at UCSF

• Letrozole in Patients With Hepatopulmonary Syndrome

  open to eligible people ages 18-99

  The purpose of this study is to assess the safety, tolerability and possible benefit of letrozole compared to placebo in patients with Hepatopulmonary Syndrome.

  San Francisco, California and other locations

Last updated: December 9, 2020